A Remote Physical Activity Program in the Population Suffering From Type 1 Myotonic Dystrophy

Myotonic Dystrophy Type 1 (DM1) Clinical Trial

Official title: A Remote Physical Activity Program Via the PACE Tool to Counter the Physical Impairments, Accentuated by the Pandemic, in the Population Suffering From Type 1 Myotonic Dystrophy

Status Recruiting

Clinical Trial Summary

The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Myotonic Dystrophy
• Myotonic Dystrophy Type 1 (DM1)

• NCT number: NCT05072288
• Study type: Interventional
• Source: Université du Québec à Chicoutimi
• Contact: Anne-Marie Fortin
• Phone: 418-590-0993
• Email: anne-marie3_fortin@uqac.ca
• Status: Recruiting
• Phase: N/A
• Start date: August 11, 2021
• Completion date: January 1, 2024